Platelet-activating factor induces ovine fetal pulmonary venous smooth muscle cell proliferation: Role of epidermal growth factor receptor transactivation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 6, 2007, Pages

  Zhou, Weilin ^a   Ibe, Basil O ^a   Raj, J Usha ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Fetal pulmonary circulation; Pulmonary vein

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALKALINE PHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; ILOMASTAT; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FETUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PULMONARY VEIN; SMOOTH MUSCLE FIBER; ZYMOGRAPHY;

ANIMALS; BACTERIAL PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; MUTATION; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLATELET ACTIVATING FACTOR; PULMONARY VEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SHEEP; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TYRPHOSTINS;

EID: 34447503630     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01018.2006     Document Type: Article

References (50)

1. Bertelsen LS, Barrett KE, Keely SJ. Gs protein-coupled receptor agonists induce transactivation of the epidermal growth factor receptor in T84 cells: implications for epithelial secretory responses. J Biol Chem 279: 6271-6279, 2004.
2. Caplan MS, Hsueh W, Sun XM, Gidding SS, Hageman JR. Circulating plasma platelet activating factor in persistent pulmonary hypertension of the newborn. Am Rev Respir Dis 142: 1258-1262, 1990.
3. Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 146: 389-397, 1995.
4. Chen Z, Rola-Pleszczynski M, Stankova J. Activation of ERK1/2 by platelet-activating factor receptor is independent of receptor internalisation and G-protein activation. Cell Signal 15: 843-850, 2003.
5. Dingemans KP, Wagenvoort CA. Pulmonary arteries and veins in experimental hypoxia. An ultrastructural study. Am J Pathol 93: 353-368, 1978.
6. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease- dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276: 7957-7962, 2001.
7. Gao Y, Zhou H, Raj JU. PAF induces relaxation of pulmonary arteries but contraction of pulmonary veins in the ferret. Am J Physiol Heart Circ Physiol 269: H704-H709, 1995.
8. Gaumond F, Fortin D, Stankova J, Rola-Pleszczynski M. Differential signaling pathways in platelet-activating factor-induced proliferation and interleukin-6 production by rat vascular smooth muscle cells. J Cardiovasc Pharmacol 30: 169-175, 1997.
9. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94: 68-76, 2004.
10. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 96: 2322-2330, 1995.
11. Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther 255: 962-968, 1990.
12. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202, 1980.
13. Hu LM, Jones R. Injury and remodeling of pulmonary veins by high oxygen. A morphometric study. Am J Pathol 134: 253-262, 1989.
14. Ibe BO, Hibler S, Raj JU. Platelet-activating factor modulates pulmonary vasomotor tone in the perinatal lamb. J Appl Physiol 85: 1079-1085, 1998.
15. Ibe BO, Pham HH, Kaapa P, Raj JU. Maturational changes in ovine pulmonary metabolism of platelet-activating factor: implications for postnatal adaptation. Mol Genet Metab 74: 385-395, 2001.
16. Ibe BO, Portugal AM, Chaturvedi S, Raj JU. Oxygen-dependent PAF receptor binding and intracellular signaling in ovine fetal pulmonary vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 288: L879-L886, 2005.
17. Ibe BO, Portugal AM, Raj JU. Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma. Int Arch Allergy Immunol 139: 225-236, 2006.
18. Ibe BO, Portugal AM, Usha Raj J. Metabolism of platelet activating factor by intrapulmonary vascular smooth muscle cells Effect of oxygen on phospholipase A2 protein expression and activities of acetyl-CoA acetyltransferase and cholinephosphotransferase. Mol Genet Metab 77: 237-248, 2002.
19. Ibe BO, Raj JU. Leukotriene metabolism by intrapulmonary vessels of newborn lambs: effect of platelet-activating factor. Exp Lung Res 27: 331-348, 2001.
20. Ibe BO, Sander FC, Raj JU. Platelet-activating factor receptors in lamb lungs are downregulated immediately after birth. Am J Physiol Heart Circ Physiol 278: H1168-H1176, 2000.
21. Ibe BO, Sander FC, Raj JU. Platelet activating factor acetylhydrolase activity in lamb lungs is up-regulated in the immediate newborn period. Mol Genet Metab 69: 46-55, 2000.
22. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann NY Acad Sci 947: 42-54; discussion 54-45, 2001.
23. Kim SJ, Masaki T, Rowley R, Leypoldt JK, Mohammad SF, Cheung AK. Different responses by cultured aortic and venous smooth muscle cells to gamma radiation. Kidney Int 68: 371-377, 2005.
24. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001.
25. Lee RM, Masaki T, Yang HS, Liu J, Chen J, Li L, Blumenthal DK, Cheung AK. Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. J Cell Biochem, 2006.
26. Lemjabbar H, Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 8: 41-46, 2002.
27. Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem 99: 1553-1563, 2006.
28. Lucchesi PA, Sabri A, Belmadani S, Matrougui K. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation 110: 3587-3593, 2004.
29. Marques SA, Dy LC, Southall MD, Yi Q, Smietana E, Kapur R, Marques M, Travers JB, Spandau DF. The platelet-activating factor receptor activates the extracellular signal-regulated kinase mitogen-activated protein kinase and induces proliferation of epidermal cells through an epidermal growth factor-receptor-dependent pathway. J Pharmacol Exp Ther 300: 1026-1035, 2002.
30. Naeye RL. Pulmonary vascular changes with chronic unilateral pulmonary hypoxia. Circ Res 17: 160-167, 1965.
31. Ohar JA, Pyle JA, Waller KS, Hyers TM, Webster RO, Lagunoff D. A rabbit model of pulmonary hypertension induced by the synthetic platelet-activating factor acetylglyceryl ether phosphorylcholine. Am Rev Respir Dis 141: 104-110, 1990.
32. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888, 1999.
33. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1333: F179-F199, 1997.
34. Raisanen A, Mennander A, Ustinov J, Paavonen T, Hayry P. Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. Transpl Int 6: 251-257, 1993.
35. Raj JU, Toga H, Ibe BO, Anderson J. Effects of endothelin, platelet activating factor and thromboxane A2 in ferret lungs. Respir Physiol 88: 129-140, 1992.
36. Ryland D, Reid L. The pulmonary circulation in cystic fibrosis. Thorax 30: 285-292, 1975.
37. Schafer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23: 991-999, 2004.
38. Schafer B, Marg B, Gschwind A, Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 279: 47929-47938, 2004.
39. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669-672, 2002.
40. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 40: 643-672, 2003.
41. Takahashi H, Soma S, Muramatsu M, Oka M, Fukuchi Y. Upregulation of ET-1 and its receptors and remodeling in small pulmonary veins under hypoxic conditions. Am J Physiol Lung Cell Mol Physiol 280: L1104-L1114, 2001.
42. Toga H, Hibler S, Ibe BO, Raj JU. Vascular effects of platelet-activating factor in lambs: role of cyclo- and lipoxygenase. J Appl Physiol 73: 2559-2566, 1992.
43. Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, Yamamori K, Hanakawa Y, Ohmoto H, Yoshino K, Shirakata Y, Matsuzawa Y, Hashimoto K, Taniguchi N. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol 151: 209-220, 2000.
44. Voisin L, Foisy S, Giasson E, Lambert C, Moreau P, Meloche S. EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors. Am J Physiol Cell Physiol 283: C446-C455, 2002.
45. Wagenvoort CA, Wagenvoort N. Pulmonary venous changes in chronic hypoxia. Virchows Arch 372: 51-56, 1976.
46. Wang H, Chakrabarty S. Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells. Oncogene 22: 2186-2191, 2003.
47. Wetzker R, Bohmer FD. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651-657, 2003.
48. Wong AP, Nili N, Strauss BH. In vitro differences between venous and arterial-derived smooth muscle cells: potential modulatory role of decorin. Cardiovasc Res 65: 702-710, 2005.
49. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 95: 989-997, 2004.
50. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 141: 4342-4348, 2000.